Treatment of cutaneous angiosarcoma of the scalp and face in Chinese patients: local experience at a regional hospital in Hong Kong

• Published in: Hong Kong medical journal = Xianggang yi xue za zhi 2018-02, Vol.24 (1), p.25-31
• Main Authors: Chow, T L, Kwan, W Wy, Kwan, C K
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Cancer Care Facilities; Cause of Death; Chemotherapy; Combined Modality Therapy; Disease; Face - pathology; Facial Neoplasms - mortality; Facial Neoplasms - therapy; Female; Hemangiosarcoma - mortality; Hemangiosarcoma - therapy; Hong Kong; Humans; Male; Medical prognosis; Neoplasm Invasiveness - pathology; Neoplasm Recurrence, Local - pathology; Neoplasm Staging; Patients; Radiotherapy, Adjuvant; Retrospective Studies; Scalp - pathology; Skin Neoplasms - mortality; Skin Neoplasms - therapy; Surgery; Tumors
• ISSN: 1024-2708; 2226-8707
• DOI: 10.12809/hkmj176813

Angiosarcoma is a rare aggressive sarcoma that occurs mostly in the skin of the head and neck in the elderly population. The optimal management is dubious and most studies are from Caucasian populations. We aimed to examine the treatment and outcome of this disease in Chinese patients. Data of patients with histopathologically verified cutaneous angiosarcoma of the head and neck during December 1997 to September 2016 were retrieved from our hospital cancer registry. The demographic data, clinicopathological information, modality of treatment, and outcomes were reviewed. During the study period, 17 Chinese patients were treated. Their median age was 81 years. The tumours were present in the scalp only (n=11), face only (n=4), or both scalp and face (n=2). Only two patients had distant metastases. The modalities of treatment were surgery (n=6), surgery and adjuvant radiotherapy (n=1), palliative radiotherapy (n=5), or palliative chemotherapy (n=3). The remaining two patients refused any treatment initially. Of the seven patients treated surgically, there were four local and two regional recurrences. The median time to relapse was 7.5 months. Overall, 16 patients had died; causes of death were disease-related in 12 whereas four other patients died of inter-current illnesses. One patient was still living with the disease. The median overall survival was 11.1 months and the longest overall survival was 42 months. The outcome of angiosarcoma in our series is poor. A high index of suspicion is mandatory for prompt diagnosis. Adjuvant radiotherapy is recommended following surgery. The benefit and role of systemic treatment in various combinations with surgery or radiotherapy require further study.